About Us


STENTYS® offers innovative solutions to the interventional cardiologist to treat patients with acute myocardial infarction and other complex coronary disease. The STENTYS product portfolio consists of the Xposition S Sirolimus-Eluting Self-Apposing® Coronary Stent System, MiStent SES® Sirolimus Eluting Absorbable Polymer Coronary Stent System, and the STENTYS AC Aspiration Catheter.

Based in France (Paris), STENTYS became listed on the Paris EuroNext stock exchange (STNT.PA) in October 2010. STENTYS® initially received CE-Marking for its STENTYS BMS and STENTYS DES(P) stents in early 2010 and currently sells its Xposition S, MiStent SES and STENTYS AC products throughout Europe, the Middle East, Latin and South America and South East Asia.

The STENTYS Clinical Program includes randomised trials and real-life registries, evaluating the STENTYS stent in STEMI with the APPOSITION program, in bifurcations with the OPEN program, and in Left Main disease with the TRUNC study. STENTYS is currently running two real-life registries, the SIZING registry (3,000 patients) and the WIN registry (750 Xposition S patients).




Contact Us

Get in touch for the latest product information.

Contact Us

Page ID 1204   |   Last edited 2017/10/16